KRYS
Income statement / Annual
Last year (2023), Krystal Biotech, Inc.'s total revenue was $50.70 M,
and the percentage change from the previous year is not available.
In 2023, Krystal Biotech, Inc.'s net income was $10.93 M.
See Krystal Biotech, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$50.70 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.03 M
|
$0.00
|
$0.00
|
| Cost of Revenue |
$8.10 M |
$4.05 M |
$2.77 M |
$1.85 M |
$974,000.00 |
$141,000.00 |
$23,000.00 |
$2,000.00 |
| Gross Profit |
$42.60 M |
-$4.05 M |
-$2.77 M |
-$1.85 M |
-$974,000.00 |
$886,000.00 |
-$23,000.00 |
-$2,000.00 |
| Gross Profit Ratio |
0.84 |
0 |
0 |
0 |
0 |
0.86 |
0 |
0 |
| Research and Development
Expenses |
$46.43 M
|
$42.46 M
|
$27.88 M
|
$17.94 M
|
$15.62 M
|
$7.76 M
|
$3.21 M
|
$741,000.00
|
| General & Administrative
Expenses |
$0.00
|
$77.74 M
|
$40.39 M
|
$15.06 M
|
$6.47 M
|
$4.16 M
|
$1.56 M
|
$402,000.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$93.39 M
|
$77.74 M
|
$40.39 M
|
$15.06 M
|
$6.47 M
|
$4.16 M
|
$1.56 M
|
$402,000.00
|
| Other Expenses |
$15.59 M |
$25.00 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$139.83 M |
$120.20 M |
$68.28 M |
$33.00 M |
$22.08 M |
$11.92 M |
$4.77 M |
$1.14 M |
| Cost And Expenses |
$147.93 M |
$120.20 M |
$68.28 M |
$33.00 M |
$22.08 M |
$11.92 M |
$4.77 M |
$1.14 M |
| Interest Income |
$22.62 M |
$5.22 M |
$197,000.00 |
$832,000.00 |
$2.99 M |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$5.22 M |
$1.49 M |
$0.00 |
$0.00 |
$1.03 M |
$3.15 M |
$7,000.00 |
| Depreciation &
Amortization |
$5.01 M
|
$4.05 M
|
$2.77 M
|
$1.85 M
|
$974,000.00
|
$141,000.00
|
$23,000.00
|
$2,000.00
|
| EBITDA |
-$92.22 M
|
-$110.92 M
|
-$65.31 M
|
-$31.15 M
|
-$21.33 M
|
-$11.78 M
|
-$4.75 M
|
-$1.14 M
|
| EBITDA Ratio |
-1.82 |
0 |
0 |
0 |
0 |
-11.47 |
0 |
0 |
| Operating Income Ratio
|
-1.92
|
0
|
0
|
0
|
0
|
-11.6
|
0
|
0
|
| Total Other
Income/Expenses Net |
$110.12 M
|
$5.22 M
|
-$1.30 M
|
$832,000.00
|
$2.99 M
|
$1.03 M
|
-$3.15 M
|
-$7,000.00
|
| Income Before Tax |
$12.90 M |
-$139.98 M |
-$69.57 M |
-$32.17 M |
-$19.09 M |
-$10.89 M |
-$7.92 M |
-$1.15 M |
| Income Before Tax Ratio
|
0.25
|
0
|
0
|
0
|
0
|
-10.6
|
0
|
0
|
| Income Tax Expense |
$1.97 M |
$34.05 M |
$2.73 M |
$1.64 M |
$576,140.00 |
-$20,141.00 |
$0.00 |
$0.00 |
| Net Income |
$10.93 M |
-$139.98 M |
-$69.57 M |
-$32.17 M |
-$19.09 M |
-$10.89 M |
-$7.92 M |
-$1.15 M |
| Net Income Ratio |
0.22 |
0 |
0 |
0 |
0 |
-10.6 |
0 |
0 |
| EPS |
0.4 |
-5.49 |
-3.13 |
-1.71 |
-1.2 |
-0.97 |
-1.48 |
-0.27 |
| EPS Diluted |
0.39 |
-5.49 |
-3.13 |
-1.71 |
-1.2 |
-0.97 |
-1.48 |
-0.27 |
| Weighted Average Shares
Out |
$27.15 M
|
$25.49 M
|
$22.20 M
|
$18.79 M
|
$15.90 M
|
$11.20 M
|
$5.36 M
|
$4.28 M
|
| Weighted Average Shares
Out Diluted |
$27.75 M
|
$25.49 M
|
$22.20 M
|
$18.79 M
|
$15.90 M
|
$11.20 M
|
$5.36 M
|
$4.28 M
|
| Link |
|
|
|
|
|
|
|
|
